Future studies should explore whether P3H4 exerts its proglycolytic effects through modulation of PI3K/AKT activity, which could provide additional therapeutic opportunities by targeting this metabolic vulnerability in HCC. The gene discussed is AKT1; the disease is hepatocellular carcinoma.